TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04801043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107
Description: XNW4107 250mg IV over 60 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107
Description: XNW4107 250mg IV over 60 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107
Description: XNW4107 250mg IV over 60 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin
Description: 500mg/500mg IV over 60 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin
Description: 500mg/500mg IV over 60 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin
Description: 500mg/500mg IV over 60 minutes as a single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo to XNW4107 containing the same inactive ingredients IV over 60 minutes as a single dose~Matching placebo to Imipenem/Cilastatin 0.9% sodium chloride IV over 60 minutes as a single dose
Study: NCT05689008

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs treatment
Description: Participants will receive two doses of UC-MSCs treatment, each dose will contain 1\*10\^6 cells/kg suspended in 100 ml albumin solution.
Study: NCT06505928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hepalatide
Description: hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hepalatide
Description: hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks
Study: NCT05980897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Naming treatment
Description: In this alternating treatment single-subject experimental design study, the investigators will alternate between two treatment conditions, i.e., two different types of stimulus items: those that are consistently reported as successful IS prior to treatment (sIS items) and those that are consistently reported as unsuccessful IS prior to treatment (uIS items). The treatment will be computerized to ensure consistency of presentation, timing, and cues across participants.~For each stimulus presentation, the treatment hierarchy will proceed as follows:~1. Name the picture independently~2. Name the picture with a written cue~3. Repeat the name of the picture~4. Name the picture after a 5 second delay Each participant will be trained on a set of 40 items chosen specifically for them based on initial/baseline testing.
Study: NCT06058611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: Cognitive stimulation through the stimulus platform; 30 minutes/day, 5 days/week, 8 weeks; 40 sessions. The following will be worked on: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulating leisure activities
Description: Intervention group 2 (IG2) will perform between 2 and 5 cognitively stimulating leisure activities for 8 weeks. These leisure activities will be selected from the adapted version of the Karp et al. 2006 questionnaire (Karp et al., 2006) taking into account the three components of leisure activities (mental, physical and social). The questionnaire contains 29 activities.~In addition to indicating which cognitively stimulating leisure activities they perform on a weekly basis, participants in IG2 will indicate their daily frequency (\< 30 min, 30min-1 hour, 1-2 hours, \> 2 hours), commenting on whether they have carried them out individually or in a group. It will also be taken into account whether these activities were previously carried out according to their stage of life.
Study: NCT05524246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Participants will receive pravastatin orally once daily through the first 35 days after bone marrow transplant.
Study: NCT05857800

Intervention type: OTHER
Intervention: Observation
Description: Analysis of dynamic changes of lung cancer microenvironment in neoadjuvant therapy using bio-omics information collected in clinical trials.
Study: NCT04710199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc experimental group
Description: 300-milligram dose of the drug two times daily , oral way. During 14 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: It is based on the treatment protocol for hospitalized COVID-19 patients and that will depend on the clinical status of the patient.
Study: NCT05383339

Intervention type: OTHER
Intervention: Blood collection
Description: - 56mL blood collected additionally to routine care
Study: NCT05646147

Intervention type: DEVICE
Group type: OTHER
Intervention: Maximal Systolic Acceleration
Description: Reliability of the maximal systolic acceleration
Study: NCT05860621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Physical Activity Counselling
Description: The brief physical activity counselling program will comprise 8 sessions (120 minutes each), every fifteen days, addressing the following themes: reasons to change, an introduction to the PAC-WOMAN program and principles, types of physical activity and their benefits, strategies on how to become more active and less sedentary, how to safely practice exercise at home, the importance of social support for doing more physical activity, barriers and facilitators for becoming more active, development of coping plans and strategies to overcome those barriers, establishing SMART goals, self-monitoring, medical aspects related to symptom management in breast cancer survivors, body image and self-acceptance, sharing experiences with role models, and re-evaluating action plans. It will be delivered in a need-supportive interpersonal climate, according to Self-Determination Theory principles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Exercise Program
Description: The structured exercise program was informed by the most recent guidelines for exercise prescription and safe practice in cancer populations. A supervised program of 32 sessions (over 4 months), lasting 90 min each, and taking place twice a week, was developed. The program combines aerobic, strength and mobility exercises, and is organized in four mesocycles, with progressive intensity, always adapted according to participants' initial assessments and evolution throughout the weeks. Once every 15 days, a thematic group class will be offered to participants, so that they can experiment and discover new physical activities, and more easily maintain regular practice in the future.
Study: NCT05198726

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alpha tACS
Description: 2mA α-tACS (based on the IAF) over the prefrontal cortex (PFC)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alpha tACS
Description: 2mA α-tACS (based on the IAF) over the prefrontal cortex (PFC)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speed of Processing Training
Description: SoP training will have a total of four conditions. In condition 1, participants will be asked to identity objects at increasingly brief exposures. For condition 2, identification of stimulus on the center of the screen will be requested from participants, while a second stimulus will appear somewhere in peripheral vision - stimulus duration, difficulty of the central localization task or the area in which targets may be located are used to change the level of difficulty. Condition 3 is similar to condition 2, but visual distractors are added. Finally, for condition 4, an auditory identification component is superimposed over the visual task (Jobe et al., 2001)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speed of Processing Training
Description: SoP training will have a total of four conditions. In condition 1, participants will be asked to identity objects at increasingly brief exposures. For condition 2, identification of stimulus on the center of the screen will be requested from participants, while a second stimulus will appear somewhere in peripheral vision - stimulus duration, difficulty of the central localization task or the area in which targets may be located are used to change the level of difficulty. Condition 3 is similar to condition 2, but visual distractors are added. Finally, for condition 4, an auditory identification component is superimposed over the visual task (Jobe et al., 2001)
Study: NCT04970290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Definisse threads free floating and definisse threads double needle
Description: Definisse threads are two class III medical devices, for evaluate the performance of the reshaping effect of the face at day 30
Study: NCT06294067

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: docosahexaenoic acid (DHA)
Description: 72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: docosahexaenoic acid (DHA)
Description: 72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: docosahexaenoic acid (DHA)
Description: 72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: docosahexaenoic acid (DHA)
Description: 72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: docosahexaenoic acid (DHA)
Description: 72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: soybean oil placebo
Description: 72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks. The 0mg group will receive only placebos.
Study: NCT06404853

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Manna
Description: Administration is by the oral route according to weight at a dosage of 1 g/kg/day, dissolved in a glass of water, up to a maximum of 30 g. Administration should be repeated every 24 h for 8 weeks, accompanied by plenty of hydration.~In case an effective dosage is achieved (evacuation within 72 h) it will be maintained until the end of the study. If evacuation has not occurred after 72 h, evacuative enema and increased dosage to 1.5 g/kg/day will be indicated. If further evacuative enema is needed, product administration will be discontinued and classical polyethylene glycol therapy will be started as per guidelines.
Study: NCT06082570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: c610 injection
Description: Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptors. The obtained c610 is used for one-time intravenous infusion.
Study: NCT06477861

Intervention type: OTHER
Intervention: calculation of the elastic power of the lung in case of the ARDS and corolating with the severity index of Berline definition of ARDS in respect to mortality and severity
Description: calculation of variables of the elastic power of the lung from the lung pressures on the ventilator : Elastic power = 0.098 \* tidal volume \* respiratory rate \* 1/2(PEEP+Pplat)

Intervention type: OTHER
Intervention: calculation of the elastic power of the lung in case of the ARDS and corolating with the severity index of Berline definition of ARDS in respect to mortality and severity
Description: calculation of variables of the elastic power of the lung from the lung pressures on the ventilator : Elastic power = 0.098 \* tidal volume \* respiratory rate \* 1/2(PEEP+Pplat)
Study: NCT06022445

Intervention type: OTHER
Intervention: CARPET prognostic model
Description: For patients diagnosed with septic shock, we obtained the information in CARPET prognostic model including time of septic shock, albumin, bilirubin, PaO2/FiO2, lactate, and GFR. We calculated the CARPET risk score and the 28-day mortality probability according to CARPET logistic regression model.
Study: NCT06186947

Intervention type: OTHER
Intervention: No intervention
Description: Participants are not subjected to any specific intervention.

Intervention type: OTHER
Intervention: No intervention
Description: Participants are not subjected to any specific intervention.
Study: NCT06355323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest CT scan
Description: chest CT scan
Study: NCT05584605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic treadmill training
Description: The intervention will be delivered based on the initial exercise testing and graded based by increasing the duration, speed and/or altitude of the treadmill training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: Interventions, such as stretching, relaxation, passive soft-tissue technics (excl. manipulation) that do not elevate the heart rate above 20HRR
Study: NCT05445063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous iPSC-derived RPE
Description: Autologous transplantation of iPSC-derived RPE
Study: NCT05994469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Copenhagen Adduction Exercise
Description: The CAE is performed by side-lying on the floor with the dominant lower limb supported in the air by a teammate, the hip is adducted until the body forms a straight line from the ankles to the shoulders (concentric phase), then the player is instructed to lower the body slowly (eccentric phase) until reaching the floor to start the next repetition.
Study: NCT05553197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 20 sessions of face-to-face, individual CBT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 20 sessions of face-to-face, individual CBT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA)
Description: Two four-week blocks of twice daily ecological momentary assessment (EMA) of symptoms and inter-session processes
Study: NCT00003564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine Hydrochloride
Description: Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine Hydrochloride
Description: Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses.
Study: NCT04810468

Intervention type: OTHER
Group type: OTHER
Intervention: Anthropometric measurment
Description: Anthropometric measurment used to asses the wheight in kelogram and asses height in cetemeter and also asses BMI
Study: NCT05979428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0491-6075
Description: NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0491-6075
Description: NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
Study: NCT05956405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIR + Mindfulness
Description: AIR + Mindfulness program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation condition
Description: Relaxation program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
Study: NCT05979428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0491-6075
Description: NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
Study: NCT04883684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal health wallet service for Chronic Patients in Emergency Department
Description: Patients(caregivers) will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
Study: NCT06129032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration (LWI) + Intraperitoneal local anaesthetic (IPLA) instillation
Description: a solution containing 20 ml of 0.5% bupivacaine, 20 ml of 2% lidocaine and 1:200,000 epinephrine with a total volume of 40 ml. A volume of 10 millilitres of the solution will be administered through the drip technique into each of the four quadrants of the uterus prior to the subsequent closure of the parietal peritoneum or fascia.~A total volume of 10 ml of the solution will be administered through infiltration at the edges of the rectus aponeurosis, while the remaining 20 ml will be infiltrated subcutaneously into the incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group QUADRATUS LUMBORUM BLOCK (QLB)
Description: quadratus lumborum type 1 block will be applied bilaterally on both sides with a total of 40 ml of solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200.000 epinephrine, under ultrasound guidance
Study: NCT05693077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E4 NTCD spores
Description: in capsule for oral ingestion.
Study: NCT05535400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical-Psychological Integrative Intervention
Description: The PPI intervention will include eight weekly online group sessions (with each session lasts for 60-90 minutes). At the beginning of each online group meeting, the intervention provider will use motivational interviewing techniques to promote participants' adherence to the physical activity program. And the content of the intervention includes eight different sessions, including Session 1- Orientation and engagement, Session 2- Awareness and Acceptance; Session 3- Non-judgement; Session 4- Stay present and let go; Session 5- Our thoughts are not real \& Response without reacting; Session 6- Empowerment of self-management and discuss pain management; Session 7- Seek out pleasant things and social support and Session 8- Review the intervention and end the programme.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brief online didactic education
Description: Participants in the control group will receive a short video call (approximately 20 minutes each week for eight weeks) from the trained research assistant, i.e., RA 2 to provide general physical and psychological suggestions (e.g., encouragement of performing physical activities, and communication skills with family members/friends, and engagement in the community life). This is to control the contact effects of the PPI intervention.
Study: NCT04636671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Per-protocol methylprednisolone administration and tapering (see arm description)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Per-protocol dexamethasone administration (see arm description)